Immune suppressive function of IL-1α release in the tumor microenvironment regulated by calpain 1

References

• Dinarello CA. Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol Rev. 2018;281(1):8–14. doi:10.1111/imr.12621.
   PubMed Web of Science ®Google Scholar
• Chiu JW, Binte Hanafi Z, Chew LCY, Mei Y, Liu H. IL-1alpha processing, signaling and its role in cancer progression. Cells. 2021;10(1):92. doi:10.3390/cells10010092.
   PubMed Web of Science ®Google Scholar
• Buryskova M, Pospisek M, Grothey A, Simmet T, Burysek L. Intracellular interleukin-1alpha functionally interacts with histone acetyltransferase complexes. J Biol Chem. 2004;279(6):4017–4026. doi:10.1074/jbc.M306342200.
   PubMed Web of Science ®Google Scholar
• Yano S, Banno T, Walsh R, Blumenberg M. Transcriptional responses of human epidermal keratinocytes to cytokine interleukin-1. J Cell Physiol. 2008;214(1):1–13. doi:10.1002/jcp.21300.
   PubMed Web of Science ®Google Scholar
• Brody DT, Durum SK. Membrane IL-1: IL-1 alpha precursor binds to the plasma membrane via a lectin-like interaction. J Immunol. 1989;143:1183–1187.
   PubMed Web of Science ®Google Scholar
• Lin D, Lei L, Liu Y, Zhang Y, Hu B, Bao G, Song Y, Jin Z, Liu C, Mei Y, et al. Membrane IL1alpha inhibits the development of hepatocellular carcinoma via promoting T- and NK-cell activation. Cancer Res. 2016;76(11):3179–3188. doi:10.1158/0008-5472.CAN-15-2658.
   PubMed Web of Science ®Google Scholar
• Afonina IS, Tynan GA, Logue SE, Cullen SP, Bots M, Luthi AU, Reeves EP, McElvaney NG, Medema JP, Lavelle EC, et al. Granzyme B-dependent proteolysis acts as a switch to enhance the proinflammatory activity of IL-1alpha. Mol Cell. 2011;44(2):265–278. doi:10.1016/j.molcel.2011.07.037.
   PubMed Web of Science ®Google Scholar
• Xu D, Mu R, Wei X. The roles of IL-1 family cytokines in the pathogenesis of systemic sclerosis. Front Immunol. 2019;10:2025. doi:10.3389/fimmu.2019.02025.
   PubMed Web of Science ®Google Scholar
• Rider P, Kaplanov I, Romzova M, Bernardis L, Braiman A, Voronov E, Apte RN. The transcription of the alarmin cytokine interleukin-1 alpha is controlled by hypoxia inducible factors 1 and 2 alpha in hypoxic cells. Front Immunol. 2012;3:290. doi:10.3389/fimmu.2012.00290.
   PubMed Web of Science ®Google Scholar
• Di Paolo NC, Shayakhmetov DM. Interleukin 1 alpha and the inflammatory process. Nat Immunol. 2016;17(8):906–913. doi:10.1038/ni.3503.
   PubMed Web of Science ®Google Scholar
• Thornton P, McColl BW, Greenhalgh A, Denes A, Allan SM, Rothwell NJ. Platelet interleukin-1alpha drives cerebrovascular inflammation. Blood. 2010;115(17):3632–3639. doi:10.1182/blood-2009-11-252643.
   PubMed Web of Science ®Google Scholar
• Dinarello CA, Ikejima T, Warner SJ, Orencole SF, Lonnemann G, Cannon JG, Libby P. Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro. J Immunol. 1987;139:1902–1910.
   PubMed Web of Science ®Google Scholar
• Menghini P, Corridoni D, Butto LF, Osme A, Shivaswamy S, Lam M, Bamias G, Pizarro TT, Rodriguez-Palacios A, Dinarello CA, et al. 2019. Neutralization of IL-1alpha ameliorates Crohn’s disease-like ileitis by functional alterations of the gut microbiome. Proc Natl Acad Sci U S A. 116(52): 26717–26726.
   PubMed Web of Science ®Google Scholar
• Gabay C, Lamacchia C, Palmer G. IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol. 2010;6(4):232–241. doi:10.1038/nrrheum.2010.4.
   PubMed Web of Science ®Google Scholar
• Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity. 2019;51(1):27–41. doi:10.1016/j.immuni.2019.06.025.
   PubMed Web of Science ®Google Scholar
• Xiao Z, Singh S, Singh M. Improving cancer immunotherapy by targeting IL-1. Oncoimmunology. 2021;10(1):2008111. doi:10.1080/2162402X.2021.2008111.
   PubMed Web of Science ®Google Scholar
• Leon X, Bothe C, Garcia J, Parreno M, Alcolea S, Quer M, Vila L, Camacho M. Expression of IL-1alpha correlates with distant metastasis in patients with head and neck squamous cell carcinoma. Oncotarget. 2015;6(35):37398–37409. doi:10.18632/oncotarget.6054.
   PubMedGoogle Scholar
• Charbonneau B,MS, Block WR, Bamlet RA, Vierkant KR, Kalli Z, Fogarty DN, Rider TA, Sellers SS, Tworoger E, Poole HA, et al. Risk of ovarian cancer and the NF-κB pathway: genetic association with IL1A and TNFSF10. Cancer Res. 2014;74(3):852–861. doi:10.1158/0008-5472.CAN-13-1051.
   PubMed Web of Science ®Google Scholar
• Kuan EL, Ziegler SF. A tumor-myeloid cell axis, mediated via the cytokines IL-1alpha and TSLP, promotes the progression of breast cancer. Nat Immunol. 2018;19(4):366–374. doi:10.1038/s41590-018-0066-6.
   PubMed Web of Science ®Google Scholar
• Dvorkin T, Song X, Argov S, White RM, Zoller M, Segal S, Dinarello CA, Voronov E, Apte RN. Immune phenomena involved in the in vivo regression of fibrosarcoma cells expressing cell-associated IL-1alpha. J Leukoc Biol. 2006;80(1):96–106. doi:10.1189/jlb.0905509.
   PubMed Web of Science ®Google Scholar
• Song X, Voronov E, Dvorkin T, Fima E, Cagnano E, Benharroch D, Shendler Y, Bjorkdahl O, Segal S, Dinarello CA, et al. Differential effects of IL-1 alpha and IL-1 beta on tumorigenicity patterns and invasiveness. J Immunol. 2003;171(12):6448–6456. doi:10.4049/jimmunol.171.12.6448.
   PubMed Web of Science ®Google Scholar
• Voronov E, Weinstein Y, Benharroch D, Cagnano E, Ofir R, Dobkin M, White RM, Zoller M, Barak V, Segal S, et al. Antitumor and immunotherapeutic effects of activated invasive T lymphoma cells that display short-term interleukin 1alpha expression. Cancer Res. 1999;59:1029–1035.
   PubMed Web of Science ®Google Scholar
• Ben-Sasson SZ, Hogg A, Hu-Li J, Wingfield P, Chen X, Crank M, Caucheteux S, Ratner-Hurevich M, Berzofsky JA, Nir-Paz R, et al. IL-1 enhances expansion, effector function, tissue localization, and memory response of antigen-specific CD8 T cells. J Exp Med. 2013;210(3):491–502. doi:10.1084/jem.20122006.
   PubMed Web of Science ®Google Scholar
• Abdel-Wahab N, Safa H, Abudayyeh A, Johnson DH, Trinh VA, Zobniw CM, Lin H, Wong MK, Abdelrahim M, Gaber AO, et al. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature. J Immunother Cancer. 2019;7(1):106. doi:10.1186/s40425-019-0585-1.
   PubMed Web of Science ®Google Scholar
• Smith MA, Schnellmann RG. Calpains, mitochondria, and apoptosis. Cardiovasc Res. 2012;96(1):32–37. doi:10.1093/cvr/cvs163.
   PubMed Web of Science ®Google Scholar
• Starling S. Innate immunity: revealing the secrets of IL-1 secretion. Nat Rev Immunol. 2017;18(1):2–3. doi:10.1038/nri.2017.155.
   PubMed Web of Science ®Google Scholar
• Hickish T, Andre T, Wyrwicz L, Saunders M, Sarosiek T, Kocsis J, Nemecek R, Rogowski W, Lesniewski-Kmak K, Petruzelka L, et al. MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2017;18(2):192–201. doi:10.1016/S1470-2045(17)30006-2.
   PubMed Web of Science ®Google Scholar
• Liu Y, Song Y, Lin D, Lei L, Mei Y, Jin Z, Gong H, Zhu Y, Hu B, Zhang Y, et al. NCR(-) group 3 innate lymphoid cells orchestrate IL-23/IL-17 axis to promote hepatocellular carcinoma development. EBioMedicine. 2019;41:333–344. doi:10.1016/j.ebiom.2019.02.050.
   PubMed Web of Science ®Google Scholar
• Hu B, Bao G, Zhang Y, Lin D, Wu Y, Wu D, Liu H. Donor NK Cells and IL-15 promoted engraftment in nonmyeloablative allogeneic bone marrow transplantation. The Journal of Immunology. 2012;189(4):1661–1670. doi:10.4049/jimmunol.1103199.
   PubMed Web of Science ®Google Scholar
• Lee CR, Kwak Y, Yang T, Han JH, Park SH, Ye MB, Lee W, Sim KY, Kang JA, Kim YC, et al. Myeloid-Derived suppressor cells are controlled by regulatory T cells via TGF-beta during murine colitis. Cell Rep. 2016;17(12):3219–3232. doi:10.1016/j.celrep.2016.11.062.
   PubMed Web of Science ®Google Scholar
• Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine selectively eliminates splenic Gr-1 + /CD11b + myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res. 2005;11(18):6713–6721. doi:10.1158/1078-0432.CCR-05-0883.
   PubMed Web of Science ®Google Scholar
• Veglia F, Sanseviero E, Gabrilovich DI. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat Rev Immunol. 2021;21(8):485–498. doi:10.1038/s41577-020-00490-y.
   PubMed Web of Science ®Google Scholar
• Lin D, Lei L, Zhang Y, Hu B, Bao G, Liu Y, Song Y, Liu C, Wu Y, Zhao L, et al. Secreted IL-1α promotes T-cell activation and expansion of CD11b + Gr1 + cells in carbon tetrachloride-induced liver injury in mice. Eur J Immunol. 2015;45(7):2084–2098. doi:10.1002/eji.201445195.
   PubMed Web of Science ®Google Scholar
• Newman AM, Steen CB, Liu CL, Gentles AJ, Chaudhuri AA, Scherer F, Khodadoust MS, Esfahani MS, Luca BA, Steiner D, et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019;37(7):773–782. doi:10.1038/s41587-019-0114-2.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Barajon I, Garlanda C. IL-1 and IL-1 regulatory pathways in cancer progression and therapy. Immunol Rev. 2018;281(1):57–61. doi:10.1111/imr.12614.
   PubMed Web of Science ®Google Scholar
• Keenan BP, Fong L, Kelley RK. Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response. J ImmunoTher Cancer. 2019;7(1):267. doi:10.1186/s40425-019-0749-z.
   PubMed Web of Science ®Google Scholar
• Refolo MG, Messa C, Guerra V, Carr BI, D’Alessandro R. Inflammatory mechanisms of HCC development. Cancers. 2020;12(3):641. doi:10.3390/cancers12030641.
   Web of Science ®Google Scholar
• Apte RN, Voronov E. Immunotherapeutic approaches of IL-1 neutralization in the tumor microenvironment. J Leukoc Biol. 2017;102(2):293–306. doi:10.1189/jlb.3MR1216-523R.
   PubMed Web of Science ®Google Scholar
• Gehrke N, Hovelmeyer N, Waisman A, Straub BK, Weinmann-Menke J, Worns MA, Galle PR, Schattenberg JM. Hepatocyte-specific deletion of IL1-RI attenuates liver injury by blocking IL-1 driven autoinflammation. J Hepatol. 2018;68(5):986–995. doi:10.1016/j.jhep.2018.01.008.
   PubMed Web of Science ®Google Scholar
• Kasprzak A, Zabel M, Wysocki J, Seidel J, Surdyk-Zasada J, Filipiak B. Expression of mRNA for cytokines (TNF-alpha and IL-1alpha) in human cytomegalovirus (HCMV) and hepatitis B virus (HBV) infections. Folia Histochemica Et Cytobiologica. 2002;40:63–68.
   PubMed Web of Science ®Google Scholar
• Steuerwald NM, Foureau DM, Norton HJ, Zhou J, Parsons JC, Chalasani N, Fontana RJ, Watkins PB, Lee WM, Reddy KR, et al. Profiles of serum cytokines in acute drug-induced liver injury and their prognostic significance. PloS one. 2013;8:e81974.
   PubMed Web of Science ®Google Scholar
• Olteanu S, Kandel-Kfir M, Shaish A, Almog T, Shemesh S, Barshack I, Apte RN, Harats D, Kamari Y. Lack of interleukin-1alpha in Kupffer cells attenuates liver inflammation and expression of inflammatory cytokines in hypercholesterolaemic mice. Digestive and Liver Disease: Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 2014;46(5):433–439. doi:10.1016/j.dld.2014.01.156.
   PubMedGoogle Scholar
• Kamari Y, Shaish A, Vax E, Shemesh S, Kandel-Kfir M, Arbel Y, Olteanu S, Barshack I, Dotan S, Voronov E, et al. Lack of interleukin-1alpha or interleukin-1beta inhibits transformation of steatosis to steatohepatitis and liver fibrosis in hypercholesterolemic mice. J Hepatol. 2011;55(5):1086–1094. doi:10.1016/j.jhep.2011.01.048.
   PubMed Web of Science ®Google Scholar
• Sakurai T, He G, Matsuzawa A, Yu GY, Maeda S, Hardiman G, Karin M. Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. Cancer Cell. 2008;14(2):156–165. doi:10.1016/j.ccr.2008.06.016.
   PubMed Web of Science ®Google Scholar
• Zhang M, Liu L, Lin X, Wang Y, Li Y, Guo Q, Li S, Sun Y, Tao X, Zhang D, et al. A Translocation Pathway for Vesicle-Mediated Unconventional Protein Secretion. Cell. 2020;181(3):637–652 e615. doi:10.1016/j.cell.2020.03.031.
   PubMed Web of Science ®Google Scholar
• Tsuchiya K, Hosojima S, Hara H, Kushiyama H, Mahib MR, Kinoshita T, Suda T. Gasdermin D mediates the maturation and release of IL-1alpha downstream of inflammasomes. Cell Rep. 2021;34(12):108887. doi:10.1016/j.celrep.2021.108887.
   PubMed Web of Science ®Google Scholar
• Pietras EM, Mirantes-Barbeito C, Fong S, Loeffler D, Kovtonyuk LV, Zhang S, Lakshminarasimhan R, Chin CP, Techner JM, Will B, et al. Chronic interleukin-1 exposure drives haematopoietic stem cells towards precocious myeloid differentiation at the expense of self-renewal. Nat Cell Biol. 2016;18(6):607–618. doi:10.1038/ncb3346.
   PubMed Web of Science ®Google Scholar
• Law AMK, Valdes-Mora F, Gallego-Ortega D. Myeloid-Derived suppressor cells as a therapeutic target for cancer. Cells. 2020;9(3):561. doi:10.3390/cells9030561.
   PubMed Web of Science ®Google Scholar
• Lu LC, Chang CJ, Hsu CH. Targeting myeloid-derived suppressor cells in the treatment of hepatocellular carcinoma: current state and future perspectives. J Hepatocellular Carcinoma. 2019;6:71–84. doi:10.2147/JHC.S159693.
   PubMed Web of Science ®Google Scholar
• Afonina IS, Muller C, Martin SJ, Beyaert R. Proteolytic processing of interleukin-1 family cytokines: variations on a common theme. Immunity. 2015;42(6):991–1004. doi:10.1016/j.immuni.2015.06.003.
   PubMed Web of Science ®Google Scholar
• England H, Summersgill HR, Edye ME, Rothwell NJ, Brough D. Release of interleukin-1alpha or interleukin-1beta depends on mechanism of cell death. J Biol Chem. 2014;289(23):15942–15950. doi:10.1074/jbc.M114.557561.
   PubMed Web of Science ®Google Scholar
• Kimura Y, Koga H, Araki N, Mugita N, Fujita N, Takeshima H, Nishi T, Yamashima T, Saido TC, Yamasaki T, et al. The involvement of calpain-dependent proteolysis of the tumor suppressor NF2 (merlin) in schwannomas and meningiomas. Nat Med. 1998;4(8):915–922. doi:10.1038/nm0898-915.
   PubMed Web of Science ®Google Scholar
• Shapovalov I, Harper D, Greer PA. Calpain as a therapeutic target in cancer. Expert Opin Ther Targets. 2022;26(3):217–231. doi:10.1080/14728222.2022.2047178.
   PubMed Web of Science ®Google Scholar
• Ono Y, Saido TC, Sorimachi H. Calpain research for drug discovery: challenges and potential. Nat Rev Drug Discov. 2016;15(12):854–876. doi:10.1038/nrd.2016.212.
   PubMed Web of Science ®Google Scholar